Richard Porter
Hoofd Techniek/Wetenschap/O&O bij UNIQURE N.V.
Vermogen: 150 801 $ op 30-04-2024
Profiel
Richard Porter is the founder of uniQure France SAS, which was founded in 2019.
He held the title of Chief Executive Officer & Director at uniQure France SAS.
Currently, Dr. Porter is the Chief Business & Scientific Officer at uniQure NV, starting in 2021.
Dr. Porter's former positions include General Manager-Product at Shire Plc from 2011 to 2014, Global Head-Scientific Business Strategy at Roche Group from 2014 to 2016, and Chief Operating Officer at Therachon AG from 2016 to 2019.
Dr. Porter obtained a doctorate degree from The University of Southampton.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
UNIQURE N.V.
0.07% | 31-03-2024 | 33 216 ( 0.07% ) | 150 801 $ | 30-04-2024 |
Actieve functies van Richard Porter
Bedrijven | Functie | Begin |
---|---|---|
UNIQURE N.V. | Hoofd Techniek/Wetenschap/O&O | 05-10-2023 |
Eerdere bekende functies van Richard Porter
Bedrijven | Functie | Einde |
---|---|---|
Therachon AG | Operationeel Directeur | 01-07-2019 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Hoofd Techniek/Wetenschap/O&O | 01-08-2016 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01-02-2014 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Oprichter | - |
Opleiding van Richard Porter
The University of Southampton | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
Therachon AG | |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |